AstraZeneca has successfully completed the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell ...

AstraZeneca completes acquisition of biotech company, EsoBiotec: Cambridge, UK Wednesday, May 21, 2025, 09:00 Hrs [IST] AstraZeneca announced the successful completion of the acqu ...

The acquisition, initially announced in March, sees AstraZeneca pay USD425 million up front, with an additional USD575 million in potential milestone payments, bringing the total consideration to up ...

AstraZeneca AZN announced that it has entered into a definitive agreement to acquire EsoBiotec for developing in vivo cell ...

Acquisition of EsoBiotec completed AstraZeneca today announced the successful completion of the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has ...

AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio. The British pharma company said Monday that it will pay $425 ...

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging field of treatments that can reprogramme immune cells inside patients ...

AstraZeneca, one of the world’s leading pharmaceutical brands, bought his company two weeks ago. Jean-Pierre Latere is his name, and his startup, EsoBiotec, was purchased by the British giant. Latere, ...

Initial clinical data from this trial are expected to be released in the second half of 2025,” said EsoBiotec Chief Scientific Officer Philippe Parone, PhD. “At ASGCT, we will present the ...